Complete Story
 

NCCN© has updated the Clinical Practice Guidelines

I am pleased to inform you that The National Comprehensive Cancer Network© (NCCN©) has updated the Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® and cetuximab or panitumumab as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after failure of one to two prior lines of therapy for metastatic disease. Please click here to see press release for full content.

 

Printer-Friendly Version